Brief: Cerenis Says Tango Phase III Study Missed Primary Endpoint

Abionyx Pharma SA

05/12/2018 07:08

Dec 5 (Reuters) - CERENIS THERAPEUTICS HOLDING SA
 CEREN.PA :
    * CERENIS ANNOUNCES THE RESULTS OF TANGO, A PHASE III
CLINICAL
STUDY EVALUATING CER-001 IN PATIENTS WITH HDL DEFICIENCY
    * MISSED PRIMARY ENDPOINT IN TANGO PHASE III STUDY
    * THERE WAS NO STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN
PLACEBO AND CER-001 TREATED GROUPS FOR PRIMARY OUTCOME
    * FURTHER DEVELOPMENT OF THE TARGETED DRUG DELIVERY HDL
PLATFORM
WILL CONTINUE
    * SAFETY AND TOLERABILITY PROFILE WAS FAVORABLE AND
CONSISTENT
WITH PREVIOUS CER-001 TRIALS
    * SAFETY AND TOLERABILITY PROFILE WAS FAVORABLE AND
CONSISTENT
WITH PREVIOUS CER-001 TRIALS
    * RESULTS OF THE MULTIPLE ASCENDING DOSE STUDY WITH CER-209
IN THE
NAFLD/NASH PROGRAM ARE EXPECTED BEFORE THE END OF THE YEAR
    * FURTHER DEVELOPMENT OF TARGETED DRUG DELIVERY HDL PLATFORM
WILL
CONTINUE

Source text for Eikon:  ID:nBwRGSkwa 
Further company coverage:  CEREN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))